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Abstract
Purpose Lung cancer remains the top cause of cancer
morbidity and mortality in the world. Although the iden-
tification of epidermal growth factor receptor (EGFR) gene
mutations could predict efficacy of tyrosine kinase inhibi-
tor (TKI), testing for predictive biomarkers are not always
possible due to tissue availability. The overall therapeutic
decision remains a clinical one for a significant proportion
of elderly patients with advanced stage lung cancer but no
known EGFR mutation status. The purpose of this study
was to compare the outcome of drug treatment modalities
in progression-free survival (PFS) and overall survival
(OS) for elderly with advanced-stage non-small cell lung
cancer (NSCLC) and to identify clinical parameters that
could predict treatment outcome.
Methods Clinical records of patients aged 70 years or older
with advanced-stage NSCLC who have received treatment
were reviewed. A group of gender- and histology-matched
subjects younger than age 70 years were identified as controls.
Results Fifty-six elderly patients were included. The
median age at diagnosis was 73 years; 60.7 % received
only one line of treatment. Baseline performance status
(PS) was the only predictor of improved PFS (p = 0.042)
and OS (p = 0.002). There was no difference in survival
between the upfront chemotherapy and the TKI groups
Conclusions In elderly with advanced-stage NSCLC
without known EGFR mutation status, use of EGFR–TKI
and chemotherapy resulted in comparable survival benefits.
Age was not predictive of worse treatment outcome. The
baseline PS should be taken into consideration in the
therapeutic decision in elderly with NSCLC where the
EGFR mutation status is not known.
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Outcome
Introduction
Lung cancer remains the top cause of cancer morbidity and
mortality worldwide [1]. In Hong Kong, lung cancer ranks
the top in cancer incidence and mortality [2]. In 2009,
4,365 new cases of lung cancer were diagnosed and this
may be the most conservative estimation as underdiagnosis
could occur in the frail and elderly [3], who may decline
invasive investigation for histological diagnosis.
With increasing life expectancy over the past decades,
the incidence of lung cancer in the elderly population is
increasing. Approximately 50 % of new lung cancer was
diagnosed in patients older than 65 years, while 30–40 %
were diagnosed in patients older than 70 years [4]. In Hong
Kong, the median age at diagnosis was 71 for men and 73
for women [2]. This subgroup does not only represent a
significant healthcare burden, but their proportion is
expected to grow with our aging population. However,
elderly patients were underrepresented in clinical trials on
cancer treatment (22 % of subjects were older than age
65 years, and 8–13 % older than age 70 years) [5]; the
proportion of elderly (i.e., [70 years of age) included in
the IDEAL 1 and 2 [6], INTACT [7, 8], IPASS [9], and
NCIC–BR21 [10] studies were 4.9, 7.5, 27, and 22 %
respectively, and the mean age of subjects in the TALENT
[11] and TRIBUTE [12] trials were 59.1 ± 10.01 and
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62.6 ± 10.1 years respectively. The results from these
clinical trials might not be directly applicable to the
elderly, as there could be diverse and variable effects of
aging on organ functions. The variety of possible comorbid
diseases also could result in heterogeneous therapeutic
response in the elderly that is different from those seen in
younger subjects. With the relative paucity of clinical trial
data, the likelihood of receiving any kind of treatment for
NSCLC, particularly chemotherapy, decreases significantly
with increasing age [13]. Pharmacokinetic differences also
may result in considerable variability in the efficacy and
safety of cancer treatments in the elderly compared with
the younger group of lung cancer subjects [14].
There were usually more female patients and adenocar-
cinoma in the younger NSCLC subjects compared with their
older counterparts, but there was no statistical difference in
the staging of lung cancer between the two age groups [15].
Data from five large clinical trials [SWOG 9509 [16], ECOG
5592 [17], ECOG 1594 [18], CALGB 9730 [19], and ECOG
4599 [20] trial] showed no difference between the young and
old NSCLC patients in terms of the overall response rate and
survival to chemotherapy treatment, but toxicity was
slightly more prominent in the elderly. The ACCP Evidence-
Based Clinical Practice Guidelines (2nd Edition, 2007)
recommended that age alone should not dictate treatment-
related decisions in patients with advanced NSCLC [21].
This recommendation was based largely on studies com-
paring younger (\70 years) with older (C70 years) patients
who participated in large, randomized trials that were not
designed to address the elderly issue. An OS of 10.9 months
was reported with the use of erlotinib [22]. In two other
studies, survival and ORR were similar between gefitinib
and vinorelbine [23] but were comparatively higher with
erlotinib.
Chen et al. [24] found that in Chinese patients with
advanced NSCLC aged 80 years or older, patients who
received EGFR–TKI therapy had a significantly better
prognosis (hazard ratio: 0.56), a benefit not found in che-
motherapy or radiotherapy group. Irisa et al. [25] found
that NSCLC histology (HR 1.631), three or more comor-
bidities (HR 1.317), and a CCI of more than three (HR
1.321) were independent negative prognostic factors. Gi-
rones et al. [26], however, found that TMN clinical staging
(log-rank: p \ 0.001), not CCI, was related to survival. Li
et al. [27] found that comorbidity, number of chemotherapy
cycles, and use of second-line therapy were identified as
independent prognostic factors (Table 1).
Although the identification of epidermal growth factor
receptor (EGFR) gene mutations could predict clinical
efficacy of tyrosine kinase inhibitor (TKI), these molecular
test for predictive biomarkers are not always possible or
available due to tissue availability or financial constraint.
Moreover, no reliable treatment outcome predictors could
be identified for EGFR wild-type patients. Elderly patients
with good PS and no major comorbid conditions seemed to
derive benefits from carboplatin-based chemotherapy.
Table 1 Summary of prognostic factors in elderly with advanced stage NSCLC
Author Sample
size (n)
Design Significant prognostic factors
Hickish
et al. [28]
290 Cisplatin chemotherapy Performance status, disease extent, pattern of metastasis
Kaneda et al.
[29]
101 Single use of gefitinib Female gender, good performance status, low level of smoking index
Clement
et al. [30]
231 Compared age \65
with C65






Platinum-based first-line chemotherapy, performance status, ORR for first-line










Include both TKI and
chemotherapy






Li et al. [27] 109 Age [70
Treated with
chemotherapy
Number of comorbidities, number of chemotherapy cycles, use of second-line therapy
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However, no study had thus far considered all the above
factors in analysis, nor has the sequence of therapy ever
considered. There was no study that looked specifically at
the tolerability of chemotherapy and TKI in elderly.
The aims of this study were to review and compare the
use of systemic chemotherapy and EGFR–TKI and the
clinical outcomes (OS, PFS, and complication rates) for




This was a single-center, retrospective cohort study in selected
elderly patients with unresectable advanced stage or meta-
static NSCLC. Clinical patient records with ICD coding of
162.0–162.9, from patients aged 70 years or older with path-
ological diagnosis of advanced stage (i.e., CStage IIIA)
NSCLC, and who had received treatment in the Department of
Medicine, Queen Mary Hospital, from 2003 to 2009, were
included. Primary endpoints were PFS and OS. OS was defined
as the time from diagnosis to death. PFS was defined as the
time from commencement of treatment to the time of docu-
mented disease progression or death, whichever came first.
Adverse events were graded using the National Cancer Insti-
tute Common Toxicity Criteria Expanded Common Toxicity
Criteria (in JBR 10) and version 2.0 of the National Cancer
Institute Common Toxicity Criteria toxicity scale (in BR 18).
Subjects younger than age 70 years, matched for gender, his-
tology, and smoking history in the same time period were
identified as the control cohort, and the OS was compared.
Clinical and Statistical Variables
The following variables were included in the analysis:
gender, smoking history, drinking history, number of
comorbidities, Charlson Comorbidity Index (CCI), Sim-
plified Comorbidity Score (SCS), primary site of the tumor,
location of metastasis, TMN stages, standardized uptake
value (SUV) in positron-emission tomography (PET-CT),
cell types, degree of differentiation reported in the histol-
ogy report, types of first-line treatment received (EGFR–
TKI vs. chemotherapy), and total numbers of lines of
treatment. Survival and complications rate also were ana-
lyzed. Kaplan–Meier analysis was used to compare sur-
vival between those aged \70 and [70 years.
Statistical Methods
The IBM PASW 17.0 was used for statistical analysis. Data
were expressed as frequency, mean, standard deviation and
range as appropriate. All tests were two-tailed, and statis-
tical significance was p B 0.05. v2 test was used for cate-
gorical variables, and Fisher’s exact test was used for
smaller group sizes (i.e., less than five in a group). Mann–
Whitney test was employed for analysis of continuous
variables. PFS and OS were assessed by Kaplan–Meier
analysis. A proportional Cox regression model was applied




A total of 1,998 lung cancer subjects with the diagnosis
coding of 162.1–162.9 (neoplasm of lung) who fulfilled the
inclusion criteria were retrieved from the Hong Kong
Hospital Authority Clinical Management System; 1,500
subjects remained after small cell lung cancer, neuroen-
docrine tumor of the lung, and cancer due to metastasis
were excluded. With the additional criteria of history of use
of EGFR–TKI (gefitinib or erlotinib) or chemotherapy
(including cisplatin, carboplatin, docetaxel, paclitaxel,
gemcitabine, vinorelbine, pemetrexed, and etoposide), 300
patients remained. Fifty-six of these patients were aged
C70 years. Of these 56 patients, the median age at the time
of diagnosis was 73 years (interquartile range (IQR),
71.25–75.00 years). Nineteen (33.9 %) patients were non-
smokers, 27 (48.2 %) were former smokers, and 10
(17.9 %) were current smokers. Nineteen (33.9 %) patients
enjoyed good past health before cancer diagnosis, and eight
(14.3 %) of these patients had a prior history of cancer in
other organ systems. CCI scores ranged from 0 to 8,
whereas SCS ranged from 0 to 6. Four (7.1 %) had a family
history of cancer. Thirty-eight (67.9 %) presented inci-
dentally, and 49 (87.5 %) had PS of 0–1 at the time of
diagnosis of lung cancer [compared with 7 (12.5 %) with
PS 2–4]. Intrapulmonary metastasis was suspected or
confirmed in 14 (25 %), brain metastasis in 3 (5.4 %), liver
metastasis in 2 (3.6 %), adrenal metastasis in 9 (16.1 %),
bone metastasis in 12 (21.4 %), pericardial effusion in 3
(5.4 %), and pleural effusion in 19 (34.5 %) of patients.
Ten patients (17.9 %) had stage IIIA, 12 (21.4 %) with
stage IIIB, and 34 (60.7 %) had stage IV disease. Twelve
(21.4 %) had NSCLC, 31 (55.4 %) had AD, and 9 (16.1 %)
had SCC. Thirty-four (60.7 %) patients received only one
line of treatment (either TKI or chemotherapy), 4 (7.1 %)
had TKI followed by chemotherapy on progression, and the
remaining 18 (32.1 %) had chemotherapy followed by TKI
on progression; 13 (23.3 %) had more than two successive
lines of different therapy. The most commonly employed
first line chemotherapy was paclitaxel–platinum doublets
Lung (2013) 191:645–654 647
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(44 %), followed by gemcitabine–platinum doublets
(28.9 %), whereas monotherapy was used as first-line
treatment in three patients (6.7 %; Table 2).
Table 2 Baseline demographics of included subjects


























C5 15 (25 %)
Family history of cancer
No 52 (92.9)
Lung cancer 2 (3.6)























































Single type 34 (60.7)
TKI then chemotherapy 4 (7.1)
Chemotherapy then TKI 18 (32.1)
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First-Line TKI Versus Chemotherapy
As shown in Table 3, there was no difference between the
first-line TKI and chemotherapy group in terms of mean
age (71 vs. 73 years; p = 0.193), smoking status, good past
health or not, prior cancer history, CCI scores, SCS scores,
family history of cancer and baseline performance status
(PS), the location of the primary tumor, and the sites of
metastasis and the overall TNM staging between the two
groups. There also was no statistical difference between the
two groups in terms of the ultimate numbers of lines of
treatment received. The only statistically significant dif-
ference was found in those who received EGFR–TKI as
first-line therapy were more likely to be female (mal-
e:female 64.3:35.7 % vs. 27.3:72.7 %; p = 0.011), and
patients who had upfront chemotherapy were more likely
to have received just one line of treatment (p \ 0.001;
Table 3).
Survival Analysis
Overall PFS and OS for the whole group of 56 patients
were ten (range 5–15) months and 19 (range 11–31)
months respectively. In univariate analysis, longer PFS
correlated with better baseline PS (Fig. 1). Gender, smok-
ing history, and cell type did not predict PFS. On the other
hand, longer OS was correlated with better baseline PS,
AD cell types, and increased lines of treatment and better
CCI scores. Age, smoking history, drinking history, SCS,
choice of upfront treatment (EGFR–TKI or chemotherapy)
and whether patients had ever used TKI were not associ-
ated with survival.
Complication Rates
The rates of severe adverse effects of chemotherapy and
EGFR–TKI are summarized in Table 4. Fourteen of 51
(27.5 %) patients who have ever undergone chemotherapy
had no complications, comparable to the eight of 27
(29.6 %) in ever-TKI group (Table 4). No factors
(including age, PS, CCI, SCS, or cell type) were found to
be predictive of treatment (both chemotherapy and TKI)
intolerance.
Subgroup Analysis
The records of 56 additional patients with advanced-stage
NSCLC but younger than age 70 years matched for gender,
histological subtypes, and smoking status to our elderly
Table 3 Comparison between upfront TKI and chemotherapy groups






Female 8 (72.7) 12 (26.7) 0.011*
Male 3 (27.3) 33 (73.3)
Smoking history
Non-smoker 5 (45.5) 14 (31.1) 0.564
Ex-smoker 5 (45.5) 22 (48.9)
Current smoker 1 (9.1) 9 (20)
Drinking history
Non-drinker 11 (100) 35 (77.8) 0.226
Ever-drinker 0 10 (22.3)
Good past health
No 5 (45.5) 32 (71.1) 0.156
Yes 6 (54.5) 13 (28.9)
Cancer history
No 11 (100) 37 (82.2) 0.333
Other cancer 0 8 (17.8)
CCI score
0 8 (72.7) 21 (46.7) 0.849
1 2 (18.2) 12 (26.7)
2 1 (9.1) 4 (8.9)
C3 0 8 (17.8)
SCS score
0 6 (54.5) 10 (22.2) 0.093
1 3 (27.3) 15 (33.3)
2 0 7 (15.6)
C3 2 (18.2) 13 (28.9)
Family history of cancer
No 10 (90.9) 42 (93.3) 0.436
Lung cancer 0 2 (4.4)
Other cancer 1 (9.1) 1 (2.2)
Incidental presentation
No 8 (72.7) 30 (66.7) 0.501
Yes 3 (27.3) 15 (33.3)
PS
0–1 9 (81.8) 40 (88.9) 0.614
2–4 2 (18.2) 5 (11.1)
Metastasis
Intrapulmonary
Suspected 2 (18.2) 3 (6.7) 0.42
Confirmed 1 (9.1) 8 (17.8)
Brain
Confirmed 1 (9.1) 2 (4.4) 0.488
Liver
Confirmed 0 2 (4.4) 0.654
Lung (2013) 191:645–654 649
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(age C70 years) cohort, were reviewed. The mean age of
this group was 47 (range 40–53.75) years. The OS was 14
(range 8–29) months, which was not significantly different
from their elderly counterparts (p = 0.075). Gender has no
significant correlation with OS (p = 0.255 and p = 0.168
for female and male subgroups respectively).
Discussion
Clinical Significance
This study gave insights into local practice of lung cancer
treatment for the elderly. The results served as a reminder
of the importance of lung cancer in the elderly and their
needs for special attention.
The survival predictors identified in this study were
different from those published by Hickish et al. [28] (PS,
extent of disease, pattern of metastasis, and age) and
Kaneda et al. [29] (female gender, good PS, low level of
smoking index). This could be the results of inclusion of
both chemotherapy- and TKI-treated elderly based on
clinical judgment. The study by Chen et al. [24] (survival
predictor—use of TKI) were similar to our study but may
not be directly comparable as patients aged 70–79 years
were excluded. On the contrary, the studies by Irisa et al.
[25] (survival predictor—histology subgroup, number of
comorbidities, and CCI score) and Girones et al. [26]
(survival predictor—TMN staging) shared the same age
cutoff of 70 years and overall study design. We have
considered all the variables mentioned in these studies, but
none was found to be a significant survival predictor; one
possible explanation of this might be a sample bias as those
with multiple comorbidities might not have been referred
for treatment. Our findings were most similar to those
demonstrated by Li et al. [27] (survival predictors—
comorbidity, chemotherapy cycles, and presence of sec-
ond-line therapy). However, EGFR–TKI use was not
included in those studies. To our knowledge, our study was
the only one currently available that reviewed specifically
Chinese elderly aged C70 years with advanced NSCLC
who has undergone treatment in accordance with contem-
porary standard of care. In addition to verifying the pre-
viously published prognostic factors, our study was the first
to look at whether inclusion of TKI in the treatment or the
choice of first-line therapy affected survival.
Although EGFR mutation status could be tested for lung
cancer patients to guide therapeutic decision for using
EGFR–TKI or not, such biomarker testing may not always
be possible or available due to tissue availability or
financial constraint. In this retrospective review of treat-
ment outcome in elderly patients with advanced-stage lung
Table 3 continued






Suspected 1 (9.1) 3 (6.7) 0.961
Confirmed 1 (9.1) 4 (8.9)
Bone
Suspected 0 1 (2.2) 0.87
Confirmed 2 (18.2) 9 (20.0)
Pericardial effusion
Suspected 0 1 (2.2) 0.679
Confirmed 0 2 (4.4)
Pleural effusion
Suspected 3 (27.3) 9 (20.5) 0.684
Confirmed 2 (18.2) 5 (11.4)
T-staging
1A 0 3 (6.7) 0.533
2A 3 (27.3) 8 (17.8)
2B 2 (18.2) 2 (4.4)
T-staging
3 2 (18.2) 10 (22.2)
4 3 (27.3) 19 (42.2)
NA 1 (9.1) 3 (6.7)
N-staging
0 3 (27.3) 4 (8.9) 0.147
1 0 5 (11.1)
2 1 (9.1) 15 (33.3)
3 6 (54.5) 20 (44.4)
NA 1 (9.1) 1 (2.2)
M-staging
0 4 (36.4) 18 (40) 0.624
1a 5 (45.5) 14 (31.1)
1b 2 (18.2) 13 (28.9)
Stage
IIIA 0 10 (22.2) 0.143
IIIB 4 (36.4) 8 (17.8)
IV 7 (63.6) 27 (60)
Cell type
AD 6 (54.5) 21 (46.7) 0.639
Non-AD 5 (45.5) 24 (53.3)
Treatment combination
Single type 5 (45.5) 29 (64.4) \0.001*
TKI then chemotherapy 4 (36.4) 0
Chemotherapy then TKI 2 (18.2) 16 (35.6)
Total lines of treatment
1 4 (36.4) 23 (51.1) 0.072
2 3 (27.3) 13 (28.9)
C3 4 (36.4) 9 (20)
* p \ 0.05
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cancer (EGFR mutation testing was not available in our
hospital service within the review period), PS was found to
be the only significant determining factor for survival
outcome in elderly subjects with advanced stage NSCLC.
Neither age nor choice of upfront treatment (chemotherapy
or TKI) was a significant predictor for survival. Tolera-
bility of chemotherapy and TKI in the elderly was similar,
and our subanalysis showed that the survival in the elderly
were similar to that of their younger counterpart. These
results suggested that the general PS of the patients, rather
than age alone, should be one clinical parameter used to
guide therapeutic decisions as to the choice between TKI
and chemotherapy. The results of this retrospective study
would pave the way for further prospective study on the
treatment of advanced stage lung cancer in elderly subjects.
The performance of CCI and SCS as two potentially
useful scores to guide treatment decision in the elderly was
reviewed in this study. CCI was a significant prognostic
factor to predict OS in univariate analysis, but not in
multivariate analysis. This could partly be explained by the
fact that CCI was designed for elderly, hospitalized
patients, and therefore might not be informative in our
NSCLC subsets who were managed as out-patient as far as
was practically possible. SCS was not found to be a sig-
nificant outcome predictor of survival. This difference from
published data was likely due to the fact that the initial SCS
derivation utilized patients from all stages of NSCLC, and
the median age of that study was only 62.5 years.
Despite the common practice (at the time) of treating
older patients with monotherapy, only three patients
(6.7 %) in our cohort received first-line monotherapy,
whereas all others received platinum-doublets. Our expe-
rience was that most doublet regimen are well tolerated in
the elderly, and this echoed the finding in the IFCT-0501
trial in which patients aged at least 70 years were ran-
domized to receive either vinorelbine or gemcitabine alone
or with monthly carboplatin combined with weekly pac-
litaxel demonstrated that there was a highly significant
benefit of survival in the doublet chemotherapy arm [30].
Even in a priori unfavourable prognostic subgroups
(patients with a PS score of two, those aged [80 years or
those with an activities of daily living scale score of \6),
doublet therapy was associated with a survival advantage
over monotherapy
The sample inclusion in this study spanned over 7 years,
during which management protocols, recommendations,
and even staging system have changed (most of our clinical
management was based on the sixth edition of the UICC
TNM Staging system and treatment suggestions). Some of
these patients could have been managed differently
Fig. 1 Kaplan–Meier curves for a PFS and b OS in relation to PS
Table 4 Comparison of adverse effects
Chemotherapy (%) TKI (%)
Grade 1 2 3 4 1 2 3 4
Neutropenia 10.7 17.9 17.9 0 0 0 0 0
Renal impairment 7.1 0 5.4 0 9.0 0 0 0
Liver impairment 1.8 3.6 1.8 0 0 0 1.8 0
Neuropathy 3.6 0 1.8 0 0 0 0 0
Skin reaction 5.4 0 0 0 12.5 16.1 1.8 1.8
Pulmonary
reaction
0 0 1.8 1.8 0 0 0 1.8
Others 0 0 0 1.8 9.0 3.6 0 1.8
Lung (2013) 191:645–654 651
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nowadays, in keeping with the most updated seventh edi-
tion of the UICC/IASLC manual for lung cancer staging.
An invariable bias in our study stems from its retrospective
design. A cardinal example would be the preponderance of
female patient in the EGFR–TKI subgroup (72.7 vs.
35.7 %), which is likely due to clinical selection bias on the
part of the treating clinicians. In addition to physicians’
clinical decision on the choice of treatment, namely dif-
ferent types of chemotherapy or TKI, patient’s choices
played an important role in the choice of treatment. Edu-
cation levels (the adequacy to understand presented infor-
mation and critical analysis ability), patient’s preference
(which might be dictated by perception in adverse effect
profile rather than efficacy), and social and financial factors
might confound treatment selection. Our study allowed for
all treatment as per protocol and practical factors, and
therefore the results obtained can provide practical infor-
mation for practicing medical practitioners and nursing
staff.
In clinical practice, invasive procedures often were not
considered for those that have poor premorbid state, based
on the rationale that patients might not be able to tolerate
any treatment even after invasive investigation. Therefore,
the included subjects in this study population might have
better pre-morbid state. EGFR mutation testing was not
widely available at the time of this study, and none of the
included patients have known EGFR mutation status.
Despite the common dictum in the pre-EGFR-testing era to
select nonsmoking women with adenocarcinoma for TKI
therapy, our data failed to show obvious association of
these features with clinical response to TKI. A possible
reason was again patients’ choice, which depends heavily
on their perceived side effect profile of the treatment.
Elderly patients and their family might choose TKI since
they believe that it is less toxic, and therefore more toler-
able, than chemotherapy.
Our finding of similar survival between elderly and their
younger counterparts echoed those published; data from
five large clinical trials [SWOG 9509 [31], ECOG 5592
[32], ECOG 1594 [33], CALGB 9730 [34], and ECOG
4599 [35] trial] found no difference between the young and
old NSCLC patients in terms of the overall response rate
and survival to chemotherapy treatment, but toxicity was
slightly more prominent in the elderly.
The survival (both PFS and OS) was significantly longer
in our study compared with existing elderly-focused trials
(e.g., ELVIS or MILES). However, the OPTIMAL trial has
shown that median PFS reached 13.1 months in patients
with EGFR-activating mutation treated with EGFR–TKI
[36]. In the iPASS trial, it was shown that PFS ranges from
5.5–6.3 months in the chemotherapy arm [9]. Based on
these two Asian-oriented trials, it can be postulated that the
observed survival in this study might be due to a significant
number of patient that have harbored EGFR-activating
mutation.
Although the small sample size of this study preclude
meaningful multivariate analysis, empirical data (not
shown in the result session) seems to point to PS as the
only significant predictive factor to PFS (HR 1.792,
CI 1.022–3.143, p = 0.042) and OS (HR 1.921, CI
1.259–2.907, p = 0.002). To confirm this, along with other
findings in this study, a similarly designed, prospective trial
with larger sample size would be informative.
It is important and warranted to include more elderly
patients in prospective clinical trials in the use of both
chemotherapy and targeted therapeutics to better determine
the factors that should aid decision to treat with chemo-
therapy or targeted therapies and to address the comparison
between doublet and single-agent therapy.
Conclusion
In elderly subjects with advanced-stage NSCLC without
known EGFR mutation status, EGFR–TKI appeared non-
inferior compared with chemotherapy. Age was not a sig-
nificant predictor of outcome but PS before primary treat-
ment could be one predictor of clinical outcome of treatment.
Further, larger, prospective studies in elderly subjects with
advanced stage NSCLC are needed to guide clinical man-
agement and therapeutic decision and to improve treatment
outcomes of elderly subjects with advanced stage NSCLC.
Acknowledgment The authors thank Ms. Amy Cheung, Ms. Chris-
tina Yan, Dr. Michelle Yuen, Dr. Harry Gill, and Dr. Tuen-Ching Chan
for their help in database management and statistical analysis.
Conflict of interest All authors of this manuscript declared no
conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. U.S. National Institute of Health (2008) SEER survival monograph.
http://seer.cancer.gov/csr/1975_2008/browse_csr.php?section=
15&page=sect_15_table.28.html. Accessed 1 Apr 2013
2. Hong Kong Hospital Authority (2009) Hong Kong Cancer Reg-
istry. http://www3.ha.org.hk/cancereg/statistics.html. Accessed 1
Apr 2013
3. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS
(1999) Underrepresentation of patients 65 years of age or older in
cancer-treatment trials. N Engl J Med 341(27):2061–2067
4. Gridelli C, Perrone F, Monfardini S (1997) Lung cancer in the
elderly. Eur J Cancer 33(14):2313–2314
652 Lung (2013) 191:645–654
123
5. Yee KW, Pater JL, Pho L, Zee B, Siu LL (2003) Enrollment of
older patients in cancer treatment trials in Canada: why is age a
barrier? J Clin Oncol 21(8):1618–1623
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K,
Douillard JY et al (2003) Multi-institutional randomized phase II
trial of gefitinib for previously treated patients with advanced
non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol
21(12):2237–2246
7. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R,
Miller V et al (2004) Gefitinib in combination with gemcitabine
and cisplatin in advanced non-small-cell lung cancer: a phase III
trial–INTACT 1. J Clin Oncol 22(5):777–7784
8. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V,
Manegold C et al (2004) Gefitinib in combination with paclitaxel
and carboplatin in advanced non-small-cell lung cancer: a phase
III trial–INTACT 2. J Clin Oncol 22(5):785–794
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N
et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary
adenocarcinoma. N Engl J Med 361(10):947–957
10. Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA (2008)
Validation of treatment induced specific adverse effect as a pre-
dictor of treatment benefit: a case study of NCIC CTG BR21.
Contemp Clin Trials 29(4):527–536
11. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De
Rosa F et al (2007) Phase III study of erlotinib in combination
with cisplatin and gemcitabine in advanced non-small-cell lung
cancer: the Tarceva lung cancer investigation trial. J Clin Oncol
25(12):1545–1552
12. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE,
Sandler A et al (2005) TRIBUTE: a phase III trial of erlotinib
hydrochloride (OSI-774) combined with carboplatin and paclit-
axel chemotherapy in advanced non-small-cell lung cancer. J Clin
Oncol 23(25):5892–5899
13. Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U,
Lacombe D et al (2010) EORTC elderly task force and lung
cancer group and international society for geriatric oncology
(SIOG) experts’ opinion for the treatment of non-small-cell lung
cancer in an elderly population. Ann Oncol 21(4):692–706
14. Aapro MS, Kohne CH, Cohen HJ, Extermann M (2005) Never
too old? Age should not be a barrier to enrollment in cancer
clinical trials. Oncologist 10(3):198–204
15. Kuo CW, Chen YM, Chao JY, Tsai CM, Perng RP (2000) Non-
small cell lung cancer in very young and very old patients. Chest
117(2):354–357
16. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK,
Moinpour CM et al (2001) Randomized phase III trial of
paclitaxel plus carboplatin versus vinorelbine plus cisplatin in
the treatment of patients with advanced non-small-cell lung
cancer: a southwest oncology group trial. J Clin Oncol
19(13):3210–3218
17. Johnson DH (1995) Phase III trial (E5592) comparing cisplatin
plus etoposide with cisplatin plus paclitaxel at two dose levels for
treatment of advanced non-small-cell lung cancer. Eastern
cooperative oncology group. J Natl Cancer Inst Monogr 19:61–63
18. Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB,
Marinucci DM et al (2010) A randomized, phase III multicenter
trial of gemcitabine in combination with carboplatin or paclitaxel
versus paclitaxel plus carboplatin in patients with advanced or
metastatic non-small-cell lung cancer. Ann Oncol 21(3):540–547
19. Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM,
Miller AA et al (2005) Single-agent versus combination che-
motherapy in advanced non-small-cell lung cancer: the cancer
and leukemia group B (study 9730). J Clin Oncol 23(1):190–196
20. Tyagi P (2005) Bevacizumab, when added to paclitaxel/carbo-
platin, prolongs survival in previously untreated patients with
advanced non-small-cell lung cancer: preliminary results from
the ECOG 4599 trial. Clin Lung Cancer 6(5):276–278
21. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R,
Sandler AB et al (2007) Treatment of non-small cell lung cancer,
stage IV: ACCP evidence-based clinical practice guidelines, 2nd
edn. Chest 132(3 Suppl):277S–289S
22. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS,
Temel J et al (2007) Phase II clinical trial of chemotherapy-naive
patients C70 years of age treated with erlotinib for advanced non-
small-cell lung cancer. J Clin Oncol 25(7):760–766
23. Crino L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson
JC et al (2008) Gefitinib versus vinorelbine in chemotherapy-
naive elderly patients with advanced non-small-cell lung cancer
(INVITE): a randomized, phase II study. J Clin Oncol
26(26):4253–4260
24. Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC (2010)
Octogenarians with advanced non-small cell lung cancer: treat-
ment modalities, survival, and prognostic factors. J Thorac Oncol
5(1):82–89
25. Irisa K, Masago K, Togashi Y, Fujita S, Hatachi Y, Fukuhara A
et al (2010) Significance of pretreatment comorbidities in elderly
patients with advanced non-small-cell lung cancer treated with
chemotherapy or epidermal growth factor receptor–tyrosine
kinase inhibitor. Med Oncol 29(1):185–192
26. Girones R, Torregrosa D, Gomez-Codina J, Maestu I, Tenias JM,
Rosell R (2011) Prognostic impact of comorbidity in elderly lung
cancer patients: use and comparison of two scores. Lung Cancer
72(1):108–113
27. Li J, Chen P, Dai CH, Li XQ, Bao QL (2009) Prognostic factors
in elderly patients with advanced non-small cell lung cancer
treated with chemotherapy. Oncology 76(5):355–362
28. Hickish TF, Smith IE, O’Brien ME, Ashley S, Middleton G
(1998) Clinical benefit from palliative chemotherapy in non-
small-cell lung cancer extends to the elderly and those with poor
prognostic factors. Br J Cancer 78(1):28–33
29. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fu-
kuoka M (2004) Retrospective analysis of the predictive factors
associated with the response and survival benefit of gefitinib in
patients with advanced non-small-cell lung cancer. Lung Cancer
46(2):247–254
30. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A
et al (2011) Carboplatin and weekly paclitaxel doublet chemo-
therapy compared with monotherapy in elderly patients with
advanced non-small-cell lung cancer: IFCT-0501 randomised,
phase 3 trial. Lancet 378(9796):1079–1088
31. Gralla RJ (1999) Silk purse in Atlanta: a commentary on SWOG
9509, an advanced non-small cell lung cancer trial. Oncologist
4(3):188–190
32. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D
et al (2002) Cisplatin-based therapy for elderly patients with
advanced non-small-cell lung cancer: implications of Eastern
cooperative oncology group 5592, a randomized trial. J Natl
Cancer Inst 94(3):173–181
33. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH
(2007) Randomized phase II trial of paclitaxel plus carboplatin or
gemcitabine plus cisplatin in Eastern cooperative oncology group
performance status 2 non-small-cell lung cancer patients: ECOG
1599. J Clin Oncol 25(4):418–423
34. Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilen-
baum R, Schilsky RL et al (2008) Measuring clinically significant
chemotherapy-related toxicities using medicare claims from
cancer and leukemia group B (CALGB) trial participants. Med
Care 46(3):303–308
35. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP,
Brahmer JR et al (2008) Outcomes for elderly, advanced-stage
Lung (2013) 191:645–654 653
123
non small-cell lung cancer patients treated with bevacizumab in
combination with carboplatin and paclitaxel: analysis of eastern
cooperative oncology group trial 4599. J Clin Oncol 26(1):60–65
36. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011)
Erlotinib versus chemotherapy as first-line treatment for patients
with advanced EGFR mutation-positive non-small-cell lung
cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,
randomised, phase 3 study. Lancet Oncol 12(8):735–742
654 Lung (2013) 191:645–654
123
